Lei Zhang
Chinese Academy of Medical Science and Blood Disease Hospital · Thrombosis and Haemostasis Diagnosis Treatment Center · Beijing Tsinghua Changgeng Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lei Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07789587 · A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia AInstitute of Hematology & Blood Diseases Hospital, China · not yet recruiting · Acquired Hemophilia A · principal investigator
- Ph4NCT07788456 · Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · ITP - Immune Thrombocytopenia · study director
- N/ANCT07788469 · A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia AInstitute of Hematology & Blood Diseases Hospital, China · not yet recruiting · Hemophilia A With Inhibitors · principal investigator
- N/ANCT07693283 · Expression of Target in Endometriotic LesionsBeijing Tsinghua Chang Gung Hospital · recruiting · Endometriosis · principal investigator
- N/ANCT07284524 · Intelligent Precision Knee Preservation System for Knee OsteoarthritisFirst Affiliated Hospital of Wenzhou Medical University · not yet recruiting · Knee Osteoarthritis (Knee OA) · study director
- Ph2NCT07232290 · Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraChengdu Zenitar Biomedical Technology Co., Ltd · recruiting · Polycythemia Vera (PV) · principal investigator
- N/ANCT07152925 · The Impact of Beta-band Transcranial Alternating Current Stimulation (tACS) on Impulse Inhibition in Adolescents With Non-suicidal Self-injuryAnhui Medical University · recruiting · Depression Disorders, Non-suicidal Self-injury · study director
- Ph2NCT07063199 · Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- Ph1/Ph2NCT06929299 · A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)Jiangsu BioJeTay Biotechnology Co., Ltd. · recruiting · Primary Immune Thrombocytopenia (ITP) · principal investigator
- Ph3NCT06922045 · Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia PatientsJiangsu BioJeTay Biotechnology Co., Ltd. · active not recruiting · Hemophilia · principal investigator
- Ph1NCT06880081 · Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)Chongqing Peg-Bio Biopharm Co., Ltd. · completed · Primary Immune Thrombocytopenia (ITP) · principal investigator
- Ph2NCT06838962 · Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- Ph2NCT06799611 · An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia (ITP), Treatment · principal investigator
- Ph1/Ph2NCT06776510 · A Clinical Study of NAD in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- N/ANCT06736730 · Mississippi Violence Injury Prevention (VIP) ProgramUniversity of Mississippi Medical Center · not yet recruiting · Gun Shot Wound · principal investigator
- Ph2NCT06594146 · Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)Keymed Biosciences Co.Ltd · active not recruiting · Primary Immune Thrombocytopenia · principal investigator
- Ph2NCT06552429 · Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd. · recruiting · Essential Thrombocythemia · principal investigator
- Ph2NCT06289166 · Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorStaidson (Beijing) Biopharmaceuticals Co., Ltd · completed · Hemophilia · principal investigator
- Ph2NCT06281327 · Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- Early Ph1NCT06238908 · Safety and Efficacy Study of NGGT003 in Hemophilia A PatientsInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia A · principal investigator
- Ph2NCT06199089 · A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- Ph2NCT06168851 · Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- Ph2/Ph3NCT06111638 · Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsShanghai Xinzhi BioMed Co., Ltd. · recruiting · Hemophilia A · study chair
- N/ANCT06107582 · Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China · recruiting · Primary Immune Thrombocytopenia · principal investigator
- Ph2NCT06094881 · A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- Ph2NCT06014775 · Anti-CD38 Antibody Treating Evans SyndromeInstitute of Hematology & Blood Diseases Hospital, China · unknown · Evan Syndrome, Treatment · principal investigator
- Ph2NCT05998759 · Telitacicept for the Treatment of Connective Tissue Disease-associated ThrombocytopeniaBeijing Hospital · recruiting · Connective Tissue Diseases, Thrombocytopenia · principal investigator
- Ph2NCT05995054 · A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · unknown · Immune Thrombocytopenia, Treatment · principal investigator
- Ph2NCT05983952 · Anti-CD38 Antibody Treating APS With ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · unknown · Antiphospholipid Syndrome, Thrombocytopenia · principal investigator
- Ph1/Ph2NCT05924997 · Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Advanced Hepatocellular Carcinoma · principal investigator
- Ph2NCT05913661 · Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic CholangiocarcinomaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms · principal investigator
- Ph4NCT05888870 · ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia A With Inhibitor · principal investigator
- Ph2NCT05870475 · Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Polycythemia Vera · principal investigator
- Ph4NCT05849740 · An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia AInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Acquired Hemophilia · principal investigator
- Ph4NCT05718856 · TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China · unknown · Primary Immune Thrombocytopenia (ITP) · principal investigator
- Ph1NCT05709288 · Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia B · principal investigator
- Ph2NCT05694767 · A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · completed · Immune Thrombocytopenia, Treatment · principal investigator
- Ph1/Ph2NCT05641610 · A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B PatientsInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia B · principal investigator
- N/ANCT05630651 · The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia B · principal investigator
- Ph2NCT05619926 · Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without InhibitorStaidson (Beijing) Biopharmaceuticals Co., Ltd · completed · Hemophilia · principal investigator
- Ph4NCT05585151 · High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized StudyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · Cerebral Atherosclerosis · principal investigator
- Ph4NCT05583838 · A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP PtsInstitute of Hematology & Blood Diseases Hospital, China · completed · Previously Treated Primary Immune Thrombocytopenia · principal investigator
- Ph2NCT05562882 · A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · unknown · Immune Thrombocytopenia · principal investigator
- N/ANCT05523128 · The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.Institute of Hematology & Blood Diseases Hospital, China · unknown · Hemophilia A · principal investigator
- Early Ph1NCT05454774 · A Study of FVIII Gene Therapy for Hemophilia AInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia A · study chair
- N/ANCT05442528 · Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis StudyShanghai Vitalgen BioPharma Co., Ltd. · unknown · Hemophilia B · principal investigator
- Ph1/Ph2NCT05441553 · A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B PatientsShanghai Vitalgen BioPharma Co., Ltd. · unknown · Hemophilia B · principal investigator
- Ph2NCT05395507 · Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential ThrombocythemiaInstitute of Hematology & Blood Diseases Hospital, China · unknown · Essential Thrombocytopenia · principal investigator
- Ph2NCT05236582 · Herombopag for Chemotherapy-induced ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Chemotherapy-induced Thrombocytopenia, Herombopag · principal investigator
- Ph2NCT05218226 · Avatrombopag for Chemotherapy-induced ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · unknown · Chemotherapy-induced Thrombocytopenia, Avatrombopag · principal investigator
- Ph2NCT05214391 · A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Treatment · principal investigator
- Ph2/Ph3NCT05203679 · Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy DrugShanghai Xinzhi BioMed Co., Ltd. · active not recruiting · Hemophilia B · study chair
- Ph2NCT05199909 · Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Antiphospholipid Syndrome, Thrombocytopenia, Treatment · principal investigator
- Early Ph1NCT05152732 · Safety and Tolerability of VGB-R04 in Patients With Haemophilia BInstitute of Hematology & Blood Diseases Hospital, China · unknown · Hemophilia B · principal investigator
- Ph1/Ph2NCT05027230 · A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With InhibitorStaidson (Beijing) Biopharmaceuticals Co., Ltd · completed · Hemophilia · principal investigator
- Ph2NCT04993885 · Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Immune Thrombocytopenia, Autoantibodies, Evan Syndrome · principal investigator
- Ph2NCT04962958 · Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgerySun Yat-Sen Memorial Hospital of Sun Yat-Sen University · completed · Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms · principal investigator
- Ph2/Ph3NCT04915482 · TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesInstitute of Hematology & Blood Diseases Hospital, China · unknown · Immune Thrombocytopenia (ITP), Autoantibodies, Evan Syndrome · principal investigator
- N/ANCT04890041 · TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 YearsInstitute of Hematology & Blood Diseases Hospital, China · unknown · Primary Immune Thrombocytopenic Purpura · principal investigator
- Ph1NCT04747964 · A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With InhibitorStaidson (Beijing) Biopharmaceuticals Co., Ltd · completed · Hemophilia · principal investigator
- N/ANCT04728841 · Gene Therapy for Chinese Hemophilia AInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia A, Gene Therapy · principal investigator
- Ph2NCT04696939 · Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer PatientsShanghai Pulmonary Hospital, Shanghai, China · unknown · Small-cell Lung Cancer, Neoadjuvant Therapy · principal investigator
- Ph4NCT04518475 · Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Primary Immune Thrombocytopenia (ITP) · principal investigator
- Ph4NCT04490590 · A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell LymphomaMingzhi Zhang · unknown · NK/T-Cell Lymphoma · principal investigator
- N/ANCT04433416 · Hypertension and Controlled Hypotension in the ElderlyZhang Lei · completed · Delirium · study director
- Ph2NCT04226950 · Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential ThrombocythemiaInstitute of Hematology & Blood Diseases Hospital, China · unknown · Essential Thrombocytopenia · principal investigator
- N/ANCT04135300 · Gene Therapy for Chinese Hemophilia BInstitute of Hematology & Blood Diseases Hospital, China · completed · Hemophilia B · principal investigator
- N/ANCT04014166 · Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · completed · Thrombocytopenia, Mesenchymal Stem Cells · principal investigator
- N/ANCT03998059 · Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia PatientsInstitute of Hematology & Blood Diseases Hospital, China · unknown · Thrombocytopenia, Splenectomy · principal investigator
- N/ANCT03963713 · Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic TumorsPeking University Third Hospital · unknown · Radiotherapy, Spine Metastases, Radiosurgery · principal investigator
- Ph2NCT03664518 · to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV InfectionInstitute of Hematology & Blood Diseases Hospital, China · completed · Thrombocytopenia Purpura, Chronic HBV Infection · principal investigator
- Ph4NCT03384277 · Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With RituximabInstitute of Hematology & Blood Diseases Hospital, China · completed · Acquired Hemophilia A · principal investigator
- N/ANCT02961413 · A Prospective Cohort Study on Drug-induced Liver Injury in China(DILI-P)Drug Induced Liver Disease Study Group · recruiting · Drug-induced Liver Injury · principal investigator
- N/ANCT02823444 · Non-Contrast Enhanced Peripheral Magnetic Resonance AngiographyUniversity of Utah · completed · Peripheral Arterial Disease, Intermittent Claudication, Peripheral Vascular Disease · principal investigator
- Ph1NCT02343536 · A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCelgene · completed · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular · study director
- Ph2NCT00737529 · A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialCelgene · completed · Mantle Cell Lymphoma · study director
- Ph2NCT00413036 · A Study of Revlimid in the Treatment of Non-Hodgkin's LymphomaCelgene · completed · Lymphoma, Non-Hodgkin's · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 12 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Proposal to Establish the Mississippi Violence Injury Prevention (VIP) ProgramUH3MD018298 · NIMHD · UNIVERSITY OF MISSISSIPPI MED CTR · fiscal years 2024 · $4,268,296 awarded in 2024Grant number is on one of their registry trials
- Mississippi Pregnancy Risk Assessment Monitoring System - Component AU01DP006233 · NCCDPHP · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2016 to 2020 · $166,780 awarded in 2020Same name and institution; not confirmed by an ID
- State Occupational Health and Safety Surveillance Program (2020-2021 Progress Report)U60OH010918 · NIOSH · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2015 to 2019 · $130,000 awarded in 2019Same name and institution; not confirmed by an ID
- Stress-rest calf muscle perfusion: a functional diagnostic test for peripheral arterial disease (PAD)R01HL135242 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2017 to 2019 · $760,702 awarded in 2019Same name and institution; not confirmed by an ID
- Mississippi Pregnancy Risk Assessment Monitoring System (MS-PRAMS)U01DP003133 · NCCDPHP · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2011 to 2015 · $126,198 awarded in 2015Same name and institution; not confirmed by an ID
- ADDRESSING ASTHMA FROM A PUBLIC HEALTH PERSPECTIVEU59EH000490 · NCEH · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2009 to 2013 · $445,414 awarded in 2013Same name and institution; not confirmed by an ID
- Mississippi Pregnancy Risk Assessment Monitoring SystemUR6DP000491 · NCCDPHP · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2006 to 2010 · $11,031 awarded in 2010Same name and institution; not confirmed by an ID
- Addressing Asthma from a Public Health Perspective (Limited)U59EH000208 · NCEH · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2006 to 2008 · $371,507 awarded in 2008Same name and institution; not confirmed by an ID
- ADDRESSING ASTHMA FROM A PUBLIC HEALTH PERSPECTIVEU59EH423193 · NCEH · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2003 to 2005 · $200,000 awarded in 2005Same name and institution; not confirmed by an ID
- PREGNANCY RISK ASSESSMENT MONITORING SYSTEMU50DP417123 · NCCDPHP · MISSISSIPPI STATE DEPARTMENT OF HEALTH · fiscal years 2000 to 2005 · $77,703 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 3416 PubMed records, and a shared surname and initials can bring in a namesake. All 3416 on PubMed
- 87 citationsRCR 31.2
- Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.N Engl J Med · 202582 citationsRCR 16.4
- 72 citationsRCR 13.1
- Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.N Engl J Med · 202672 citationsRCR 35.9
- 63 citationsRCR 13.8
- 55 citationsRCR 16.0
- 53 citationsRCR 15.7
- Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.Nat Med · 202550 citationsRCR 16.8
- 45 citationsRCR 22.6
- 43 citationsRCR 7.7